Protein Therapeutics begins Phase II

Protein Therapeutics (Tucson, Ariz.) began a double-blind, placebo-controlled Phase II trial of its oral human gammaglobulin (IgPO) to treat severe juvenile rheumatoid arthritis. The 8-week study in 5...